Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors inside the central anxious system, conolidine modulates alternate molecular targets. A Science Advancements analyze uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://jonathanr690tka3.wikisona.com/user